Xencor Inc Contracts & Agreements
82 Contracts & Agreements
- Business Finance (12 contracts)
- Business Operations (15)
- Human Resources (30)
- Intellectual Property (8)
- Real Estate (9)
- Uncategorized (8)
- Amended and Rest (Filed With SEC on February 29, 2024)
- Executive Employment Agreement Addendum dated November 7, 2023 by and between the Company and Celia Eckert (Filed With SEC on November 8, 2023)
- Executive Employment Agreement Addendum dated November 7, 2023 by and between the Company and Nancy Valente (Filed With SEC on November 8, 2023)
- Royalty Purchase Agreement, entered into on November (Filed With SEC on November 7, 2023)
- Royalty Purchase Agreement, entered into on November (Filed With SEC on November 7, 2023)
- First Amendment to Collaboration and License Agreement, dated January 30, 2023, by and between the Company and Janssen Biotech, Inc (Filed With SEC on August 3, 2023)
- Second Amendment to Option and License Agreement dated November 28, 2022 by and between the Company and Alexion Pharma International Operations Limited (as successor to Alexion... (Filed With SEC on February 27, 2023)
- First Amendment to Option and License Agreement dated June14, 2019 by and between the Company and Alexion Pharma Holding (as successor to Alexion Pharmaceuticals, Inc.) (Filed With SEC on February 27, 2023)
- Xencor, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 27, 2023)
- Sixth Amendment to Lease, dated November 14, 2022, by and between the Company and 111 Lemon Investors LLC (Filed With SEC on February 27, 2023)
- Second Amendment to Lease, dated August 2, 2022, by and between the Company and AG-LC 465 North Halstead Owner, L.P (Filed With SEC on November 7, 2022)
- First Amendment to Office Lease, dated May 19, 2022, by and between the Company and PRII High Bluffs LLC and Collins Corporate Center Partners, LLC (Filed With SEC on August 3, 2022)
- Xencor, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 24, 2022)
- Second Amendment to the Collaboration and License Agreement, dated June 30, 2021, by and between the Company and Genentech, Inc., and F. Hoffmann-La Roche LTD (Filed With SEC on August 4, 2021)
- Agreement of Lease, dated April 30, 2021, by and between the Company and Angelo Gordon Real Estate, Inc (Filed With SEC on August 4, 2021)
- First Amendment to Lease, dated July 13, 2021, by and between the Company and Angelo Gordon Real Estate, Inc (Filed With SEC on August 4, 2021)
- First Amendment to the Collaboration and License Agreement, dated March 10, 2021, by and between the Company and Genentech, Inc. and F. Hoffmann-La Roche LTD (Filed With SEC on May 5, 2021)
- Form of Restricted Stock Unit Agreement (Filed With SEC on March 10, 2021)
- Second Amendment to the License Agreement, dated January 8, 2020, by and between the Company and MorphoSys AG (Filed With SEC on February 24, 2021)
- Third Amendment to the License Agreement, dated July 13, 2020, by and between the Company and MorphoSys AG (Filed With SEC on February 24, 2021)
- Fifth Amendment to Lease, dated October 31, 2020, by and between the Company and 111 Lemon Investors LLC (Filed With SEC on February 24, 2021)
- Amendment to the Cross-License Agreement, dated January 2, 2020, by and between the Company and MedImmune, LLC (Filed With SEC on February 24, 2021)
- First Amendment to the Research and License Agreement, dated November 22, 2019, by and between the Company and Amgen Inc (Filed With SEC on February 24, 2021)
- Fourth Amendment to Lease, dated September 30, 2020, by and between the Company and 111 Lemon Investors LLC (Filed With SEC on November 6, 2020)
- Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on November 6, 2020)
- Third Amendment to Lease, dated April 30, 2020, by and between the Company and 111 Lemon Investors LLC (Filed With SEC on August 5, 2020)
- Employment Agreement dated November 13, 2019 by and between the Company and Dr. Allen Yang, M.D., Ph.D (Filed With SEC on February 25, 2020)
- Employment Agreement dated August 5, 2019 by and between the Company and Celia Eckert (Filed With SEC on February 25, 2020)
- Description of the Common Stock of the Company (Filed With SEC on February 25, 2020)
- Xencor, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on November 5, 2019)
- Transition and Separation Agreement and Release, executed June 21, 2019, by and between the Company and Paul Foster (Filed With SEC on August 7, 2019)
- Xencor, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on November 5, 2018)
- Transition and Separation Agreement, executed July 31, 2018, by and between the Company and Edgardo Baracchini, Jr (Filed With SEC on August 7, 2018)
- Underwriting Agreement, dated March 20, 2018 (Filed With SEC on March 21, 2018)
- Xencor, Inc. 2013 Equity Incentive Plan and Form of Stock Option Agreement and Form of Stock Option Grant Notice thereunder (Filed With SEC on February 28, 2018)
- Xencor, Inc. 2013 Employee Stock Purchase Plan (Filed With SEC on February 28, 2018)
- XENCOR, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on May 10, 2017)
- 4,585,000 Shares Xencor, Inc. COMMON STOCK, PAR VALUE $0.01 PER SHARE UNDERWRITING AGREEMENT November 30, 2016 (Filed With SEC on December 1, 2016)
- AMENDMENT NO. 1 TO COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on November 2, 2016)
- Xencor, INC. SEVERANCE AGREEMENT (Filed With SEC on August 3, 2016)
- Xencor, INC. SEVERANCE AGREEMENT (Filed With SEC on August 3, 2016)
- Xencor, INC. SEVERANCE AGREEMENT (Filed With SEC on August 3, 2016)
- Xencor, INC. SEVERANCE AGREEMENT (Filed With SEC on August 3, 2016)
- Xencor, INC. SEVERANCE AGREEMENT (Filed With SEC on August 3, 2016)
- XENCOR, INC. EMPLOYMENT AGREEMENT (Filed With SEC on March 8, 2016)
- RESEARCH AND LICENSE AGREEMENT (Filed With SEC on November 4, 2015)
- FIRST AMENDMENT TO GPEx®-DERIVED CELL LINE SALES AGREEMENT (Filed With SEC on August 5, 2015)
- 7,500,000 Shares Xencor, Inc. COMMON STOCK, PAR VALUE $0.01 PER SHARE UNDERWRITING AGREEMENT February 24, 2015 (Filed With SEC on February 25, 2015)
- AMENDMENT TO LEASE (Filed With SEC on February 20, 2015)
- Master Services Agreement (Filed With SEC on February 20, 2015)
- XENCOR, INC. EMPLOYMENT AGREEMENT (Filed With SEC on November 10, 2014)
- XENCOR, INC. 2013 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: NOVEMBER 1, 2013 APPROVED BY THE STOCKHOLDERS: , 2013 IPO DATE: , 2013 (Filed With SEC on November 4, 2013)
- XENCOR, INC. 2013 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: NOVEMBER 1, 2013 APPROVED BY THE STOCKHOLDERS: , 2013 (Filed With SEC on November 4, 2013)
- XENCOR, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on November 4, 2013)
- DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT (Filed With SEC on November 4, 2013)
- CROSS-LICENSE AGREEMENT (Filed With SEC on November 4, 2013)
- COLLABORATION AND OPTION AGREEMENT (Filed With SEC on October 25, 2013)
- [Number] Shares Xencor, Inc. COMMON STOCK, PAR VALUE $0.01 PER SHARE UNDERWRITING AGREEMENT [Date], 2013 (Filed With SEC on October 25, 2013)
- GPEx-DERIVED CELL LINE SALE AGREEMENT by and between Catalent Pharma Solutions LLC and Xencor, Inc. (Filed With SEC on October 25, 2013)
- DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT (Filed With SEC on October 25, 2013)
- COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on October 25, 2013)
- Xencor, Inc.111 West Lemon AvenueMonrovia, CA 91016Attn: Bassil Dahiyat, CEOFax: +1 ###-###-#### Copy: Morisson & forester LLP (Filed With SEC on October 25, 2013)
- CLINICAL SUPPLY AGREEMENT (Filed With SEC on October 25, 2013)
- OPTION AND LICENSE AGREEMENT (Filed With SEC on October 25, 2013)
- COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on October 11, 2013)
- XENCOR, INC. THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (Filed With SEC on October 11, 2013)
- INDEMNITY AGREEMENT (Filed With SEC on October 11, 2013)
- XENCOR, INC. 2010 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: FEBRUARY 18, 2010 APPROVED BY THE STOCKHOLDERS: DECEMBER 17, 2010 AMENDED BY THE BOARD OF DIRECTORS:... (Filed With SEC on October 11, 2013)
- OPTION AND LICENSE AGREEMENT (Filed With SEC on October 11, 2013)
- CLINICAL SUPPLY AGREEMENT (Filed With SEC on October 11, 2013)
- COLLABORATION AND OPTION AGREEMENT (Filed With SEC on October 11, 2013)
- Xencor, Inc.111 West Lemon AvenueMonrovia, CA 91016Attn: Bassil Dahiyat, CEOFax: +1 ###-###-#### Copy: Morisson & forester LLP (Filed With SEC on October 11, 2013)
- XENCOR, INC. 2013 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: , 2013 APPROVED BY THE STOCKHOLDERS: , 2013 IPO DATE: , 2013 (Filed With SEC on October 11, 2013)
- DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT (Filed With SEC on October 11, 2013)
- GPEx-DERIVED CELL LINE SALE AGREEMENT by and between Catalent Pharma Solutions LLC and Xencor, Inc. (Filed With SEC on October 11, 2013)
- XENCOR, INC. AMENDED AND RESTATED CHANGE IN CONTROL AGREEMENT (Filed With SEC on October 11, 2013)
- XENCOR, INC. AMENDED AND RESTATED SEVERANCE AGREEMENT (Filed With SEC on October 11, 2013)
- XENCOR, INC. THIRD AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT for Dr. Bassil Dahiyat (Filed With SEC on October 11, 2013)
- AMENDED CONSULTING AGREEMENT (Filed With SEC on October 11, 2013)
- XENCOR SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT for Dr. Bassil Dahiyat (Filed With SEC on October 11, 2013)
- XENCOR, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Filed With SEC on October 11, 2013)
- XENCOR, INC. 2013 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: , 2013 APPROVED BY THE STOCKHOLDERS: , 2013 (Filed With SEC on October 11, 2013)